Twist Bioscience (NASDAQ:TWST) Hits New 1-Year High - What's Next?

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report)'s share price hit a new 52-week high during trading on Tuesday. The stock traded as high as $187.87 and last traded at $179.60, with a volume of 2196788 shares trading hands. The stock had previously closed at $182.83.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on TWST shares. Leerink Partners increased their price target on Twist Bioscience from $120.00 to $160.00 and gave the company an "outperform" rating in a research note on Thursday, September 17th. Barclays lifted their price objective on Twist Bioscience from $65.00 to $95.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 24th. TD Cowen reissued a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Canaccord Genuity Group increased their target price on Twist Bioscience from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Finally, UBS Group assumed coverage on Twist Bioscience in a report on Wednesday, September 9th. They set a "neutral" rating and a $144.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $103.00.

Twist Bioscience Trading Down 1.8%

The business's 50-day moving average price is $128.74 and its two-hundred day moving average price is $88.35. The company has a market capitalization of $11.26 billion, a P/E ratio of -80.90 and a beta of 2.22. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same period last year, the firm earned $0.33 EPS. Twist Bioscience's quarterly revenue was up 23.2% on a year-over-year basis. As a group, analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other Twist Bioscience news, insider Dennis Cho sold 412 shares of the business's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $122.62, for a total value of $50,519.44. Following the completion of the transaction, the insider directly owned 73,651 shares of the company's stock, valued at approximately $9,031,085.62. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 294 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $165.49, for a total value of $48,654.06. Following the completion of the sale, the senior vice president owned 116,720 shares of the company's stock, valued at $19,315,992.80. This trade represents a 0.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 521,777 shares of company stock valued at $78,416,543. Insiders own 3.08% of the company's stock.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Twist Bioscience in the second quarter valued at $600,191,000. William Blair Investment Management LLC acquired a new position in Twist Bioscience in the 2nd quarter valued at about $223,722,000. Bank of America Corp DE acquired a new position in Twist Bioscience in the 2nd quarter valued at about $94,922,000. Allspring Global Investments Holdings LLC acquired a new stake in Twist Bioscience during the first quarter worth approximately $22,563,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Twist Bioscience during the second quarter worth approximately $19,722,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.